Hepatocyte TRAF3 promotes insulin resistance and type 2 diabetes in mice with obesity

Molecular Metabolism

Volumn 4, Issue 12, 2015, Pages 951-960

  Chen, Zheng ^a,b   Canet, Mark J ^a   Sheng, Liang ^a   Jiang, Lin ^a   Xiong, Yi ^a   Yin, Lei ^a   Rui, Liangyou ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NORTHEAST NORMAL UNIVERSITY   (China)

Author keywords

Diabetes; Gluconeogenesis; Inflammation; Insulin; Liver; Obesity; TRAF3

Indexed keywords

ALBUMIN; CRE RECOMBINASE; CYTOKINE; PROTEIN KINASE B; PYRUVIC ACID; STREPTOZOCIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

ADENOVIRUS INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME PHOSPHORYLATION; FATTY LIVER; FEMALE; GENE DELETION; GENE OVEREXPRESSION; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOBLOTTING; IMMUNOCOMPETENT CELL; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; KNOCKOUT MOUSE; LIPID DIET; LIVER CELL; LIVER HISTOLOGY; LIVER LEVEL; LOXP SITE; MALE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; POSITIVE FEEDBACK; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84961822631     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2015.09.013     Document Type: Article

References (31)

1. Rui L. Brain regulation of energy balance and body weight. Reviews in Endocrine & Metabolic Disorders 2013, 14:387-407.
2. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
3. Shoelson S.E., Goldfine A.B. Getting away from glucose: fanning the flames of obesity-induced inflammation. Nature Medicine 2009, 15:373-374.
4. Lumeng C.N., Saltiel A.R. Inflammatory links between obesity and metabolic disease. Journal of Clinical Investigation 2011, 121:2111-2117.
5. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
6. Rui L. Energy metabolism in the liver. Comprehensive Physiology 2014, 4:177-197.
7. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
8. Chawla A., Nguyen K.D., Goh Y.P. Macrophage-mediated inflammation in metabolic disease. Nature Reviews Immunology 2011, 11:738-749.
9. Glass C.K., Olefsky J.M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metabolism 2012, 15:635-645.
10. Chen Z., Shen H., Sun C., Yin L., Tang F., Zheng P., et al. Myeloid cell TRAF3 promotes metabolic inflammation, insulin resistance, and hepatic steatosis in obesity. American Journal of Physiology Endocrinology and Metabolism 2015, 308:E460-E469.
11. Sun S.C. The noncanonical NF-kappaB pathway. Immunological Reviews 2012, 246:125-140.
12. Hacker H., Redecke V., Blagoev B., Kratchmarova I., Hsu L.C., Wang G.G., et al. Specificity in toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 2006, 439:204-207.
13. Oganesyan G., Saha S.K., Guo B., He J.Q., Shahangian A., Zarnegar B., et al. Critical role of TRAF3 in the toll-like receptor-dependent and -independent antiviral response. Nature 2006, 439:208-211.
14. Hacker H., Tseng P.H., Karin M. Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nature Reviews Immunology 2011, 11:457-468.
15. Saha S.K., Pietras E.M., He J.Q., Kang J.R., Liu S.Y., Oganesyan G., et al. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. EMBO Journal 2006, 25:3257-3263.
16. Watanabe T., Asano N., Fichtner-Feigl S., Gorelick P.L., Tsuji Y., Matsumoto Y., et al. NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway. Journal of Clinical Investigation 2010, 120:1645-1662.
17. Liao G., Zhang M., Harhaj E.W., Sun S.C. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. Journal of Biological Chemistry 2004, 279:26243-26250.
18. Bista P., Zeng W., Ryan S., Bailly V., Browning J.L., Lukashev M.E. TRAF3 controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta receptor. Journal of Biological Chemistry 2010, 285:12971-12978.
19. Zarnegar B., Yamazaki S., He J.Q., Cheng G. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proceedings of the National Academy of Sciences U. S. A. 2008, 105:3503-3508.
20. He L., Grammer A.C., Wu X., Lipsky P.E. TRAF3 forms heterotrimers with TRAF2 and modulates its ability to mediate NF-{kappa}B activation. Journal of Biological Chemistry 2004, 279:55855-55865.
21. Zhu S., Pan W., Shi P., Gao H., Zhao F., Song X., et al. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. The Journal of Experimental Medicine 2010, 207:2647-2662.
22. Matsuzawa A., Tseng P.H., Vallabhapurapu S., Luo J.L., Zhang W., Wang H., et al. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science 2008, 321:663-668.
23. Tseng P.H., Matsuzawa A., Zhang W., Mino T., Vignali D.A., Karin M. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nature Immunology 2010, 11:70-75.
24. Zhou Y., Jiang L., Rui L. Identification of MUP1 as a regulator for glucose and lipid metabolism in mice. Journal of Biological Chemistry 2009, 284:11152-11159.
25. Chen Z., Morris D.L., Jiang L., Liu Y., Rui L. SH2B1 in beta-cells regulates glucose metabolism by promoting beta-cell survival and islet expansion. Diabetes 2014, 63:585-595.
26. Gardam S., Sierro F., Basten A., Mackay F., Brink R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008, 28:391-401.
27. Sheng L., Liu Y., Jiang L., Chen Z., Zhou Y., Cho K.W., et al. Hepatic SH2B1 and SH2B2 regulate liver lipid metabolism and VLDL secretion in mice. PLoS One 2013, 8:e83269.
28. Sheng L., Zhou Y., Chen Z., Ren D., Cho K.W., Jiang L., et al. NF-kappaB-inducing kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action. Nature Medicine 2012, 18:943-949.
29. Zarnegar B.J., Wang Y., Mahoney D.J., Dempsey P.W., Cheung H.H., He J., et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nature Immunology 2008, 9:1371-1378.
30. Vallabhapurapu S., Matsuzawa A., Zhang W., Tseng P.H., Keats J.J., Wang H., et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nature Immunology 2008, 9:1364-1370.
31. Chen Z., Sheng L., Shen H., Zhao Y., Wang S., Brink R., et al. Hepatic TRAF2 regulates glucose metabolism through enhancing glucagon responses. Diabetes 2012, 61:566-573.